Company intelligence / Profile preview

Y&M

Mississauga, Ontario, Canadaaki.org.in ↗

Ownership: Private
Development stage: Other

Overview

YM BioSciences developed several oncology-focused assets, most notably the JAK inhibitor CYT387 with positive Phase 2 results in myelofibrosis. Nimotuzumab advanced through multiple international trials and received Orphan Drug Designation from the FDA. The company was acquired by Gilead Sciences in February 2013 to further develop its lead asset into pivotal studies.

Therapeutic areas: HematologyImmunologyOncology
Modalities: Small moleculeMonoclonal antibodyInhaled drug formulation
Industry: Biotech

Partnerships

Centro de Inmunología Molecular/CIMAB S.A. Cuba for nimotuzumab development/licensing

Beyond the preview

Go deeper on Y&M.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y&M.

Explore the full profile